Spinal Cord Stimulation Market - Forecasts from 2024 to 2029

The spinal cord stimulation market was valued at US$2.428 billion in 2022.

Thin cables (the electrodes) and a tiny battery pack resembling a pacemaker make up spinal cord stimulators. The generator is positioned beneath the skin, often close to the buttocks or belly, and the electrodes are positioned in the epidural space, which is where the spinal cord and vertebrae meet. The remote control's antenna is also external to the body.

Growing geriatric population globally

The spinal cord stimulation market is expected to expand more quickly due to the aging population. Around 1.5 billion people will reach 65 years of age or older by 2050, according to the World Health Organization, with emerging countries contributing the majority of this rise. Globally, people are living longer. Today, the majority of individuals may anticipate living into their 60s and beyond. The number of older people and their share of the population are increasing in every nation on earth.

One in six individuals on the planet will be 60 or older by 2030. At this period the percentage of the population aged 60 years and older will climb from 1 billion in 2020 to 1.4 billion. Therefore, the aging population, which is more prone to chronic illnesses such as neurological diseases, is what is driving the spinal cord stimulation market growth.

Increasing prevalence of complex regional pain syndrome

Changes in skin tone and temperature are other symptoms of complex regional pain syndrome. All of these alterations are the result of aberrant microcirculation brought on by nerve injury that regulates blood flow and body temperature. Some people experience trauma or injury that results in soft tissue damage, sprains, fractures, limb immobilization, or all of the above. The degenerative disc disease is anticipated to develop at the quickest rate and fuel the spinal cord stimulation market.

Increase in awareness of spinal cord stimulation

The spinal cord stimulation industry is anticipated to grow as individuals and healthcare professionals become more aware of spinal cord stimulation devices. Healthcare professionals are advising these devices as a realistic therapy option for chronic pain and other spinal problems as patients are becoming more aware of their advantages. The cost of spinal cord stimulation devices has decreased for patients due to various reimbursement programs offered by several governments and insurance companies.

Rising popularity for minimally invasive approaches and wireless technologies

Spinal cord stimulators are increasingly being implanted using minimally invasive methods. These methods shorten recuperation durations, lessen surgical trauma, and improve patient comfort. Additionally, wireless technological advancements have made it possible to remotely program spinal cord stimulators. With the use of external devices or smartphone applications, patients may customize their device's settings for more easy pain treatment. This plays a key driver for the spinal cord stimulation market.

Enhancement in Technology

The spinal cord stimulation industry is expanding due to technical developments in spinal cord stimulation devices. Modern features like longer battery life, and better programming are being added to new gadgets. These developments are boosting the use of spinal cord stimulation devices and enhancing patient outcomes. Innovative spinal cord stimulation devices being introduced by the medical device sector to meet the unmet medical demands of a sizable target audience are anticipated to offer profitable chances for spinal cord stimulation market growth.

Use of AI in spinal cord stimulation

In spinal cord stimulation, AI is being utilized to improve the accuracy of the electrical impulses delivered by the stimulator. This is accomplished by continuously tracking and gathering information about the patient's health, and utilizing that information to modify the stimulator's settings. This enables a more individualized treatment strategy and could ultimately improve patient results. The number of adverse effects connected to existing spinal cord stimulator therapies may also be decreased with the use of AI which is a major growth driver for the spinal cord stimulation market. AI is being used to identify illnesses, forecast patient outcomes, and even suggest individualized treatment plans.

In North America, it is projected that the spinal cord stimulation market would grow steadily.

North America is anticipated to dominate the worldwide spinal cord stimulation market due to an increase in occurrences of chronic pain, failing back syndrome, and CRPS. Additionally, the existence of well-established healthcare facilities, the availability of highly qualified doctors, and rising awareness of spinal cord stimulation therapy will propel the North American market. Rapid spinal cord stimulation market growth is also anticipated as a result of the rapid adoption of technologically improved items.

The United States is anticipated to hold the maximum market share

The United States is the largest spinal cord stimulation industry in the North American region, and this industry's growth is predicted to be boosted by increased product launches and commercialization agreements with important manufacturers and other businesses. For instance, the spinal cord stimulation market growth of spinal cord stimulators (SCS) is anticipated to be boosted in January 2021 by the recent launch of Boston Scientific's WaveWriter Alpha line of SCS devices.

Market Key Developments

• In May 2023, according to a statement from Abbott, the U.S. Food and Drug Administration (FDA) authorized the use of its spinal cord stimulation (SCS) devices to treat people with persistent back pain.
• In October 2022, The Senza HFX iQ spinal cord stimulation (SCS) device, which includes AI, was authorized by the FDA.
• In August 2022, the new ProclaimTM Plus spinal cord stimulation (SCS) device from Abbott, which uses FlexBurst360TM treatment, gained FDA clearance.
• In January 2022, The U.S. Food and Drug Administration has approved the use of the rechargeable neurostimulators IntellisTM and VantaTM by Medtronic plc, a world leader in healthcare technology, to treat chronic pain brought on by diabetic peripheral neuropathy (DPN).

Segmentation:

By Product

• Rechargeable
• Non-rechargeable

By Disease Indication

• Failed Back Surgery Syndrome
• Degenerative Disc Disease
• Complex Regional Pain Syndrome
• Arachnoiditis
• Others

By End-User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others